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Background: Perimembranous Ventricular Septal Defect (PMVSD) is the most common subtype of ventricular septal defects. Transcatheter closure of PMVSD is a challenging procedure in management of moderate or large defects.
Objectives: The purpose of this study was to show that transcatheter closure of perimembranous ventricular septal defect with Amplatzer Ductal Occluder (ADO) is an effective and safe method.
Patients and Methods: Between April 2012 and April 2013, 28 patients underwent percutaneous closure of PMVSD using ADO. After obtaining the size of VSD from the ventriculogram a device at least 2 mm larger than the narrowest diameter of VSD at right ventricular side was chosen. The device deployed after confirmation of its good position by echocardiography and left ventriculography. Follow up evaluations were done 1 month, 6 months, 12 months and yearly after discharge with transthoracic echocardiography and 12 lead electrocardiography.
Results: The mean age of patients at procedure was 4.7 ± 6.3 (range 2 to 14) years, mean weight 14.7 ± 10.5 (range 10 to 40) kg. The mean defect size of the right ventricular side was 4.5 ± 1.6 mm. The average device size used was 7.3 ± 3.2mm (range 4 to 12 mm). The ADOs were successfully implanted in all patients. The VSD occlusion rate was 65.7% at completion of the procedure, rising up to 79.5% at discharge and 96.4% during follow-up. Small residual shunts were seen at completion of the procedure, but they disappeared during follow-up in all but one patient. The mean follow-up period was 8.3 ± 3.6 months (range 1 to 18 months). Complete atrioventricular block (CAVB), major complication or death was not observed in our study.
Conclusions: Transcatheter closure of PMVSD with ADO in children is a safe and effective treatment associated with excellent success and closure rates, but long-term follow-up in a large number of patients would be warranted.
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1. BackgroundAmong congenital heart defects (CHD), Ventricular septal defect (VSD) is the most common form. VSD ap-proximately constitutes for 30% of congenital heart dis-eases and by newer echocardiography and experience of echocardiographers now the recognition of VSDs is increased up to 50/1000 live births and bigger rates in human fetuses (1-4). Perimembranous ventricular sep-tal defect (PMVSD) is the most common subtype of this defect and responsible for more than 85% of VSDs. Small VSDs (less than one third of aortic valve size) do not cause significant pulmonary overload or overcirculation and do not increase pulmonary/systemic blood flow (QP/QS) significantly. Medical treatment, surgical therapy or in-terventional closure of these defects is not suggested and the outcome of these patients with these small defects is very good. In cases with increased pulmonary flow and moderate or larger defects surgical or interventional ap-
proach is recommended. Compared to surgical approach with a history of 60 years’ experience, transcatheter closure of PMVSD is a newer procedure. Because of the shorter hospitalization time and not needing cardiopul-monary bypass and sternotomy, transcatheter approach is recommended in some types of VSD. Amplatzer for VSD closure was added to interventional management before 2000 for the first time and the Amplatzer Membranous VSD Occluder for closing of membranouse defects was first described after 2000 and added to muscular VSD Oc-cluder (5-7). The Ampltzer perimembranous ventricular septal defect occluder (APMVSDO) has shown to be effec-tive in closing PMVSD in several papers (8, 9). One of the most serious complications of this method is high inci-dence of atrioventricular conduction block (AVB) (10-13). Comparing surgical closure and percutaneouse closure of isolated VSD, early and delayed atrioventricular block 
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was described in less than 1% of patients after surgical closure, whereas this complication ranges from 3% to 20% after percutaneous closure (12, 14). The proximity of the His bundle and the right ventricular disc of the APM-VSDO and the squeezing effect of both discs and induc-ing of fibrous tissue formation during the time by device implantation may cause complete atrioventricular block (CAVB) after transcatheter closure of PMVSD by using an APMVSDO.
2. ObjectivesThe purpose of this study was to evaluate the results of our experience in early and mid-term follow up of trans-catheter closure of VSD using Amplatzer ductal occluder (ADO) in children because it has shorter left ventricular rim and no right ventricular disc and no squeezing effect and therefore, it is supposed to have lower incidence of CAVB.
3. Patients and MethodsThe study protocol was approved by the Ethics Com-mittee of the Iran University of Medical Sciences in Iran. In this study all patients who had undergone transcath-eter closure of VSD using ADO between April 2012 and April 2013 in Shaheed Rajaee Cardiovascular Medical and Research Center were included. Parental consent was obtained for this study. In this period of time 28 pa-tients underwent transcatheter closure of PMVSD using ADO. Patients were examined by a standard echocardio-graphic protocol and experienced operator; all patients underwent transthoracic echocardiography (TTE) that was performed with a GE Vivid 3 machine including M-mode, two-dimensional and color Doppler. The standard technique was used to obtain the measurements in a non-sedated for older children and sedated for younger children in quiet and wakeful state. Size and sort of VSD were examined in different standards four chambers, five chambers and parasternal in short and long-axis views. Patients with clinical or echocardiographic evidence of significant left to right shunt whose Qp/Qsws was ≥ 1.5 due to isolated PMVSD, were selected and included in the study. A significant left-to-right shunt was considered to be a perimembranous ventricular septal defect and the following data were found: (a) prominent cardiomegaly and lung congestion on standard chest X-ray; (b) left atrial to aortic ratio > 1.5 in long axis parasternal view examination by echocardiography defined as left atrial enlargement; (c) left ventricular overload and enlarge-ment in echocardiography; (d) frequent respiratory in-fections in past medical history (six events during a year) and/or failure to thrive; (e) Infants selected for transcath-eter VSD closure that weighed ≥ 10 kg. Exclusion criteria were (a) VSD associated with any other congenital heart disease which had to be corrected by surgical approach; (b) patients with significant non-cardiac and cardiac co-morbidities and abnormalities that could impact clinical 
outcome of VSD closure; (c) VSD with severe pulmonary artery hypertension (Eisenmenger syndrome) and right to left shunt or pulmonary vascular resistance of greater than 8 Woods units; (d) patients with perimembranous VSD and prolapse of an aortic cusp; (e) sepsis and (f) con-traindication to antiplatelet therapy.Percutaneous closure of a VSD was performed under general anesthesia. Femoral vein and arterial line were obtained. For procedure we gave 100 IU/kg heparin in two divided doses (50 IU/kg at first and 50 IU/kg half an hour later) for each patient to maintain activated clot-ting time longer than 200 sec after obtaining the femoral artery. Intravenous antibiotic with 30 mg/kg Cefazoline was administered prophylactically at beginning of the procedure and two subsequent doses 8 hours during the following 24 hours. The procedure was performed under fluoroscopic and transthoracic echocardiographic (TTE) control. Standard right and left cardiac catheterization and angiography were performed and data was gath-ered. During the cardiac procedure angiographic and catheterization data including size and type of VSD, its relation to aorta and being of an aneurysmal formation of VSD were obtained from the ventriculogram in left-an-terior-oblique (LAO) in different degree’s and also right-anterior-oblique (RAO) views for relation by pulmonary artery (Figure 1).
Figure 1. Left Ventriculogram at the Beginning of Procedure for Estima-tion of Perimembrous VSD Size and Relation to Aortic Valve
LAO aortogram in ascending aorta was obtained for identifying of aortic cusp prolapse. Right and left ventric-ular pressures, pulmonary artery pressure and fluoros-copy time were identified via right and left cardiac study. Total time of procedure was estimated from beginning to the end of procedure. The diameter of pulmonic end of 
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chosen ADO was at least 2 mm larger than the narrowest of the measured VSD diameter in right side by ventriculo-gram. Subsequently, a 0.035 inch Terumo glide wire was placed across the VSD using a 4 or 5 French curved end-hole catheter (Judkins right coronary, Cobra) or manu-ally cutting a pig-tail catheter to adjust the needed angle from the left ventricle (LV) into either branch of the pul-monary artery, and superior or inferior vena cava. At the next step the wire was snaring with Amplatz Gooseneck Snare and withdrawn to exteriorize it through femoral vein and establishing a long wire loop from the femoral artery to the femoral vein. Over this wire, an appropriate size dilator and long sheath was advanced from the femo-ral vein across the VSD by standard protocol all the way until the tip of the sheath was in the descending aorta (Figure 2).
Figure 2. Left Ventriculogram After Advancing of an Appropriately Sized Sheath From the Femoral Vein Across the VSD
Then the dilator was removed from the vein line and guide wire and end-hole catheter were removed from arterial line. At this time for measuring of VSD diameter ventriculogram was repeated. After flushing the long sheath, the device was loaded under a blood/saline solu-tion and the device attached to the delivery sheath and advanced to the tip of the sheath during fluoroscopy. At this time the retention disc of the ADO device was de-ployed and following which the cable delivery sheath and device were pulled as one unit under fluoroscopy un-til the retention disk was positioned at the left ventricu-lar side of VSD not interfering with aortic valve cusps. At this stage left ventriculography and echocardiography were performed to confirm appropriate device position and aortogram to confirm absence of aortic regurgita-tion. The tubular frame of the ADO device was deployed by pulling the sheath in to the right ventricle. The device 
was released by turning the cable after confirmation of good device position. Aortogram and left ventriculogram were taken 5 - 10 minutes after releasing the device (Fig-ure 3). Chest X ray (CXR), complete blood cell counts (CBC) and echocardiography were done 4-6 hours later for ear-ly complication such as occult hemorrhage, pulmonary complication and pericardial effusion. Urine analysis for exclusion of hemolysis was done the day after procedure. Vital signs monitoring was done during first 24 hours. The patients were monitored with electrocardiogram for 24 hours. 12 -lead electrocardiogram was obtained one day, one month, three months and yearly after the device implantation. Echocardiography was performed one day, one month, three months, 12 months and yearly after discharge. All patients received Clopidogrel 1 mg/kg for three days and 0.5 mg/kg for one month, acetyl salislic acid (ASA) 3-5 mg/kg for six months and heparin 50 IU/kg every six hours for first day by control of clotting tests. All patients were discharged 24 hours after procedure. Endocarditis prophylaxis was done for first six months if needed and discontinued at the six month's follow-up by echocardiography if the defect was completely occluded and had no residue. Data are expressed as a frequency or percentage for nominal variables. Continuous variables are expressed as Mean ± standard deviation (SD). Analy-ses were performed by using SPSS Statistics 18.0. Statisti-cal significance was defined as a P value < 0.05.
Figure 3. Left Ventriculogram After Releasing of ADO in the Perimembra-nous VSD Shows Well Positioned ADO in Aneurysm of VSD
4. ResultsDuring the period of the study, with the intention to close the VSD, 28 patients underwent transcatheter closure of VSD between April 2012 and April 2013. Mean 
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duration of follow-up was 8.3 ± 3.6 months (range 1 to 18 months). We had 16 female and 12 male patients. Table 1 shows demographic, general, clinical, and analytical data of the patients. All 28 patients showed LV enlargement in echocardiographic examination. Fifteen patients showed PMVSD with aneurysm. The defects were successfully closed in 27/28 (96.4%) patients. We had no mortality or major arterial complications such as massive bleeding or femoral arteriovenous fistula. Hemolysis did not happen in any patient. Mild thrombosis of right or left femoral artery and reducing arterial pulse occurred in 4 patients. Arterial surgical consult and Doppler sonographic study were done for all these patients. Intravenous infusion of heparin produced a successful and complete turn of pulse without sequel. No patient needed femoral artery thrombectomy. Device embolization did not occur in any patient. No aortic valve regurgitation was observed in our patients. In five patients, transient arrhythmia such as tachycardia and bradycardia was seen during different maneuvers of the catheter or guide wire. As the procedure stopped, sinus rhythm recovered quickly. Transient AVB was found in one patient during different maneuvers of the catheter or guide wire during proce-dure, but disappeared quickly without any management, so the procedure was continued to implant the device successfully. After discharge of hospital during follow-up no deaths or cases of infectious endocarditis occurred in our patients. In cases with aneurysmal PMVSD we tried to occlude larger hole in left ventricle with Amplatzer but in two patients Amplatzers were implanted in an-eurysmal sac and in one of these patients we had mild residual shunt (by echocardiographic evidence) during follow-up. Ventricolography at the end of the procedure demonstrated that complete occlusion rate was 65.7% im-mediately after completion of the procedure, rising up to 79.5% at discharge and 96.4% during follow-up. The com-plete heart block did not happen during the follow-up pe-
riod. Follow up to this time (1 month - 18 months) showed no significant complications such as device embolization or malposition, thrombus or clot formation, hemolysis or thromboembolism.
5. DiscussionThis study reports results and follow-up findings in 28 children who underwent transcatheter closure of VSD using Amplatzer PDA. Transcatheter closure of VSD like other interventional approaches has complications such as femoral artery thrombosis and arterial complications, hemolysis and embolization of the device. However, the high incidence of complete atrioventricular block (CAVB) after device closure of a PMVSD has been a seri-ous and worrisome complication (10-15). The CAVB rates reported in most reports is around 5% of CAVB. Predescu reported higher incidence (8, 9, 12). In patients treated percutaneously for closing VSD Butera et al reported that the occurrence of CAVB compared with surgical closing is a late complication, CAVB usually appears soon af-ter the surgery (11). There are no definite data about the mechanisms responsible for the occurrence of CAVB after percutaneous closure of a PMVSD. This complication has been reported to occur within a few days to months after successful and uncomplicated procedure (16-18). It is sug-gested that occurrence of CAVB after interventional clo-sure of PMVSD with APMVSDO is caused by an oversize de-vice through direct compression and traumatizing of the surrounding tissue that provokes inflammatory reaction or scar formation and induces CAVB in conductive tis-sue (10). The occurrence of CAVB is mostly related to the anatomy of conduction system in the heart and around the margins of the defect, so both surgical and interven-tional approaches could induce complete heart block. By pointing out the anatomy of conduction pathway can be understood what causes such a high rate of CAVB. After originating of His bundle from atrioventricular node and
Table 1. Demographic Data of the Patients a,b
Variant Total Male Female Range (Total)
Age, y 4.7 ± 6.3 5.1 ± 6.2 4.4 ± 4.6 2 - 14
Weight, kg 14.7 ± 10.5 15.8 ± 14.4 14.1 ± 12.2 10 - 40
VSD size at right ventricle, mm 4.5 ± 1.6 4.4 ± 1.5 4.7 ± 1.6 2.8 - 9.2
PA pressure Systolic 32.9 ± 17.2 35.2 ± 18.1 31.2 ± 11.1 18 - 52Diastolic 15.7 ± 8.1 17.1 ± 8.9 15.1 ± 7.6 12 - 39Mean PA pressure, mmHg 21.7 ± 6.2 24.2 ± 6.8 20.1 ± 5.5 12 - 37
Fluoroscopy time, min 15.4 ±8 .7 14.1 ± 12.1 15.9 ± 8.7 9.7 - 38.5
Total angiography time, min 43 ± 14.3 41.5 ± 11.6 43.9 ± 12.9 38 - 80
Size of Amplatzer (narrowest size at right ventricle), mm 7.3 ± 3.2 7.6 ± 3.1 6.4 ± 2.9 4 – 12a  Data are presented as Mean ± SD or Ranges.b  Sample size are as follows: Total = 28; Male = 12; Femal = 16.
Ghaderian M et al.
5Iran J Pediatr. 2015;25(2):e386
piercing the tricuspid valve (TV) annulus, it reaches ventricular septum and goes along the posteroinferior margin of the membranous septum. Then it divides into left bundle branch (LBB) and right bundle branch (RBB) and these divide further into smaller branches. Left bundle branch passes through the ventricular septum and right bundle branch through intramyocardium. By using Amplatzer, the ventricular septum which has a conduction pathway, could be squeezed by the two discs of the device, and as time passes, fibrotic changes occur between the device and the septum and CAVB may occur. In addition, as the device is too stiff and especially if an oversized device was chosen, it could facilitate more traumatic and inflammatory reaction in the conductive tissue.For these reasons we used ADOs that have shorter distal rim than other devices and have not a proximal disc, thus it does not squeeze His bundle and causes less CAVB. Lee et al. used ADO for closing PMVSD and they had no CAVB in their patients (19). We had also no CAVB in our patients immediately and during follow-up. Transient AVB was found in one patient during procedure because of differ-ent maneuvers of the catheter, but disappeared quickly without any management and the procedure was con-tinued successfully. In our series, the median follow-up period was 8, (3 ± 3.6 months range 1 to 18 months) and CAVB was not seen in any patient; a long term follow-up is needed for more evaluation.Some studies reported initial successful reversal or pre-vention of CAVB using steroids but one study reported of reappearance of complete atrioventricular block requir-ing a definitive pacemaker implantation after an initial successful reversal using both steroids and aspirin (10, 20, 21). We did not use steroids for prevention of pace-maker implantation in our patients. Complete AVB may occur in completely asymptomatic and healthy patients and CAVB should be monitored as a late event occurring in post procedural phases during follow-up. The occur-rence of CAVB was completely unpredictable and some patients appeared years after the device closure (22). Percutaneous closure of PMVSD in young children must be carefully suggested because CAVB occurred mostly in patients with less than five years old at the time of the procedure. In follow-up we monitor our patients with routine twelve lead ECG in every visit and if needed by 24 or 48 hours ECG holter monitoring. However, in our study no early and mid-term major complication such as mortality, CAVB, device emboli, arteriovenous fistula, he-molysis and endocarditis occurred. This study confirmed effectiveness of transcatheter closure of PMVSD using ADO during follow up. A limitation of our study was its mid-term follow-up duration.Transcatheter closure of VSD with ADO in symptomatic infants is an effective and safe method for the treatment of medium to large VSD. The low incidence of complica-tions such as CAVB and short hospital stay makes ADO ideal for transcatheter closure of medium to large VSD in 
children. For evaluation of this method long term follow-up and more study with larger number of patients is sug-gested.
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